×
To start your customized experience click the start button
Customize ?  
Start
Cancer Types
Quick Links
Award Programs
About Us
Careers
Contact Us
Newsroom
Privacy Policy
Terms & Conditions
 
Twitter
Face Book
YouTube
Instagram
 
 
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

MPN

Brielle Urciuoli
"The objective is to equip the research and drug development communities with the data needed to move better MPN treatments, and potentially, cures, through the discovery pipeline more quickly."
 
Kristie L. Kahl
A national survey demonstrated shared feelings across all blood cancer types about treatment options and their side effects, as well as other social, financial and emotional aspects.
The award recognizes individuals and organizations who are making a difference in the myeloproliferative neoplasm community
Brielle Urciuoli
The Food and Drug Administration (FDA) has granted a priority review to a new drug application (NDA) for glasdegib to treat patients with previously untreated acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC), which is a type of chemotherapy, according to Pfizer, the manufacturer of the drug.
Brielle Urciuoli
While JAK inhibitors have proven to be an effective treatment for patients with myelofibrosis, a type of myeloproliferative neoplasm (MPN), they may come with a severe downside – in particular, a 16-fold increase in the chance of developing a B-cell lymphoma, according to recent research published in the journal Blood.
Brielle Urciuoli
An MPN diagnosis can be overwhelming, but here are some of the basic facts every newly diagnosed patient should know.
Trine Alma Knudsen, M.D.
An expert discusses a trial comparing recombinant interferon alpha-2 with hydroxyurea in patients with myeloproliferative neoplasms (MPNs).
Barbara Abernathy, Ph.D.
After finding out she had an MPN, Barbara Abernathy, Ph.D., like many other people, felt numb. But then it was time to find her fight mode.
Brielle Urciuoli
With the study of more biomarkers for MPNs, the field continues to advance. However, more work still needs to be done.
Shannon Richmond
×
×

Sign In

Not a member? Sign up now!
Continue without login
Continue
×

Sign Up

Patient Caregiver Advocate Other